Clinical-stage biopharma company Seelos Therapeutics Inc. (NASDAQ: SEEL) reported financial results and clinical updates corresponding to the first quarter ended March 31, 2023.
Quarterly numbers show:
-
Total cash and cash equivalents of $14.1 million as of March 31, 2023, compared to the $15.5 million held in Dec. 31, 2022.
-
R&D expenses totaled $5.7 million compared to $10.0 million in the same period in 2022.
-
G&A expenses of $4.1 million compared to $4.0 million in 2022’s same period, plus other expenses of $4.5 million as compared to income of $9,000 in 2022’s same period.
-
Net loss of $13.4 million or $0.12 per basic and diluted share, compared to $14.0 million or $0.13 per basic and diluted share for the same period in 2022.
-
Net revenue of $808,000 compared to zero during the same period in 2022, reportedly attributed …